News - Cardio-vascular, Amgen

Filter

Current filters:

Cardio-vascularAmgen

Popular Filters

ACC 2014: Amgen’s evolocumab reduces cholesterol by up to 66%

ACC 2014: Amgen’s evolocumab reduces cholesterol by up to 66%

31-03-2014

USA-based Amgen announced data at the American College of Cardiology 63rd Annual Scientific Session this…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

More positive Ph III data for Amgen’s evolocumab

More positive Ph III data for Amgen’s evolocumab

17-03-2014

Leading independent biotech firm Amgen has released more positive clinical trial data with its cholesterol…

AmgenBiotechnologyCardio-vascularevolocumabRare diseasesResearch

Amgen announces top-line results from Phase III trial of evolocumab

Amgen announces top-line results from Phase III trial of evolocumab

29-01-2014

USA-based Amgen announced that the Phase III LAPLACE-2 trial evaluating evolocumab (AMG 145) in combination…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

Amgen’s evolocumab beats Zetia in Ph III GAUSS-2 trial for cholesterol reduction

Amgen’s evolocumab beats Zetia in Ph III GAUSS-2 trial for cholesterol reduction

24-01-2014

USA-based Amgen yesterday revealed positive results from the Phase III GAUSS-2 (Goal Achievement After…

AmgenBiotechnologyCardio-vascularevolocumabResearchZetia

Amgen reports positive results from Phase III trial of evolocumab for high cholesterol

Amgen reports positive results from Phase III trial of evolocumab for high cholesterol

18-12-2013

USA-based biotech company Amgen (Nasdaq: AMGN) has revealed positive top-line Phase III results for its…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

Amgen’s PCSK9 inhibitor evolocumab reduces cholesterol in Phase II study

Amgen’s PCSK9 inhibitor evolocumab reduces cholesterol in Phase II study

20-11-2013

USA-based biotech firm Amgen (Nasdaq: AMGN) has said its investigational PCSK9 inhibitor evolocumab helped…

AmgenBiotechnologyCardio-vascularevolocumabNorth AmericaResearchUSA

Amgen's US deal with Servier cleared

13-08-2013

USA-based Amgen (Nasdaq: AMGN), the world's leading independent biotech firm, and privately-held French…

AmgenBiotechnologyCardio-vascularLicensingNorth AmericaPharmaceuticalProcoralanServier

Amgen gains rights to Servier's heart drugs ivabradine and S38844

10-07-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, has entered a new collaboration…

AmgenBiotechnologyCardio-vascularEuropeivabradineLicensingNorth Americaomecamtiv mecarbilPharmaceuticalS38844Servier

Amgen and Cytokinetics expand omecamtiv mecarbil accord

12-06-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech company, has expanded its strategic…

AmgenAsia-PacificBiotechnologyCardio-vascularCytokineticsLicensingomecamtiv mecarbil

Amgen and Astellas link up on drugs for unmet medical needs in Japan

29-05-2013

World leading independent biotech firm Amgen (Nasdaq: AMGN) has joined forces with Japanese drug major…

AmgenAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaBiotechnologyCardio-vascularOncologyPharmaceuticalResearch

Amgen's Aranesp fails in heart patients; to invest $200 million in Singapore

18-01-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, announced top-line results…

AmgenAranespAsia-PacificBiotechnologyCardio-vascularProductionResearch

Strong mid-stage results for Amgen's cholesterol drug candidate AMG 145

07-11-2012

Global biotech leader Amgen (Nasdaq: AMGN) has announced positive results from the AMG 145 Phase II GAUSS…

AMG 145AmgenBiotechnologyCardio-vascularPfizerPharmaceuticalResearchRN316

Amgen's Sensipar/Mimpara fails to meet endpoint in CV events for dialysis patients

11-06-2012

Amgen (Nasdaq: AMGN), the world's largest independent biotech company, announced top-line results on…

AmgenBiotechnologyCardio-vascularMimparaNephrology and HepatologyResearchSensipar

NICE recommendations on Bayer's Xarelto and Amgen Xgeva's for UK NHS use

30-03-2012

Following the receipt of further evidence from Bayer HealthCare, a unit of German drugmaker Bayer (BAY:…

AmgenBayerCardio-vascularEuropeOncologyPharmaceuticalPricingRegulationXareltoXgeva

Janssen files Xarelto sNDA for ACS; FDA to review Amgen’s Xgeva for CRPC

30-12-2011

US health care giant Johnson & Johnson’s (NYSE: JNJ) Janssen Research & Development, has submitted…

AmgenBayerBiotechnologyCardio-vascularJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRegulationXareltoXgeva

UK NICE nixes three colorectal cancer drugs; gives nod to blood thinner Eliquis

25-11-2011

In a batch of mixed news coming from the UK’s National Institute for Health and Clinical Excellence…

AmgenAvastinBristol-Myers SquibbCardio-vascularEliquisErbituxMerck & CoMerck SeronoOphthalmicsPfizerPharmaceuticalPricingRegulationRocheVectibix

Not faster, but longer - new drug omecamtiv mecarbil changes beat in treating heart failure

21-08-2011

A new drug which offers a radically different approach to treating certain types of heart failure has…

AmgenCardio-vascularCytokineticsomecamtiv mecarbilPharmaceuticalResearch

Back to top